Identification

Name
Ulobetasol
Accession Number
DB00596  (APRD01010)
Type
Small Molecule
Groups
Approved
Description

Ulobetasol (as ulobetasol propionate) is thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. It is used for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Structure
Thumb
Synonyms
  • 21-chloro diflorasone
  • Halobetasol
  • Ulobetasol
  • Ulobétasol
  • Ulobetasolum
Product Ingredients
IngredientUNIICASInChI Key
Ulobetasol propionate91A0K1TY3Z66852-54-8BDSYKGHYMJNPAB-LICBFIPMSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
UltravateOintment.5 mg/gTopicalRanbaxy Inc.2009-02-20Not applicableUs
UltravateLotion.5 mg/gTopicalSun Pharmaceutical Industries Limited2016-03-01Not applicableUs
UltravateCream.5 mg/gTopicalRanbaxy Inc.2009-03-16Not applicableUs
Ultravate CreamCream0.05 %TopicalValeant Canada Lp Valeant Canada S.E.C.1993-12-31Not applicableCanada
Ultravate Ointment 0.05%Ointment0.05 %TopicalValeant Canada Lp Valeant Canada S.E.C.1993-12-31Not applicableCanada
Ultravate PACOintment.5 mg/gTopicalSun Pharmaceutical Industries Limited2008-05-13Not applicableUs
Ultravate PAC-CreamCream.5 mg/gTopicalSun Pharmaceutical Industries Limited2010-02-10Not applicableUs
Ultravate XKitRanbaxy Inc.2012-07-09Not applicableUs
Ultravate XKitRanbaxy Inc.2012-07-01Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Halobetasol PropionateCream.5 mg/gTopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.2004-12-16Not applicableUs
Halobetasol PropionateCream.5 mg/gTopicalRebel Distributors2007-07-16Not applicableUs
Halobetasol PropionateCream.5 mg/gTopicalPerrigo New York Inc.2008-08-04Not applicableUs
Halobetasol PropionateOintment.5 mg/gTopicalH.J. Harkins Company2009-02-05Not applicableUs
Halobetasol PropionateOintment.5 mg/gTopicalGw Pharmaceuticals Ltd.2007-04-27Not applicableUs
Halobetasol PropionateCream.5 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.2005-08-04Not applicableUs
Halobetasol PropionateOintment.5 mg/gTopicalPhysicians Total Care, Inc.2005-12-05Not applicableUs
Halobetasol PropionateOintment.5 mg/gTopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.2004-12-16Not applicableUs
Halobetasol PropionateOintment.5 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.2004-12-16Not applicableUs
Halobetasol PropionateOintment.5 mg/gTopicalPerrigo New York Inc.2009-02-05Not applicableUs
International/Other Brands
Halobetasol (Fougera) / Halovate (Glenmark) / Hobs (Aamorb)
Categories
UNII
9P6159HM7T
CAS number
98651-66-2
Weight
Average: 428.9
Monoisotopic: 428.1565934
Chemical Formula
C22H27ClF2O4
InChI Key
LEHFPXVYPMWYQD-XHIJKXOTSA-N
InChI
InChI=1S/C22H27ClF2O4/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-19(15,2)21(14,25)17(27)9-20(13,3)22(11,29)18(28)10-23/h4-5,7,11,13-14,16-17,27,29H,6,8-10H2,1-3H3/t11-,13-,14-,16-,17-,19-,20-,21-,22-/m0/s1
IUPAC Name
(1R,2S,8S,10S,11S,13S,14R,15S,17S)-14-(2-chloroacetyl)-1,8-difluoro-14,17-dihydroxy-2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES

Pharmacology

Indication

For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Structured Indications
Pharmacodynamics
Not Available
Mechanism of action

Halobetasol propionate is thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. The initial interaction, however, is due to the drug binding to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes.

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Human
Absorption

The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity of the epidermal barrier. Inflammation and/or other disease processes in the skin may increase percutaneous absorption.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Ulobetasol is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Ulobetasol.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Ulobetasol.Approved, Experimental, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ulobetasol.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Ulobetasol.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Ulobetasol.Approved, Withdrawn
AldesleukinUlobetasol may decrease the antineoplastic activities of Aldesleukin.Approved
AlmasilateThe bioavailability of Ulobetasol can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Ulobetasol.Experimental
AloglutamolThe bioavailability of Ulobetasol can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Ulobetasol.Experimental
AluminiumThe bioavailability of Ulobetasol can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of Ulobetasol can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Ulobetasol can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Ulobetasol can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Ulobetasol.Approved
AmiodaroneThe serum concentration of Ulobetasol can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BUlobetasol may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Ulobetasol.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Ulobetasol.Investigational
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Anthrax immune globulin human.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Ulobetasol.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Ulobetasol.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Ulobetasol.Approved, Investigational
AprepitantThe serum concentration of Ulobetasol can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Ulobetasol can be increased when it is combined with Atazanavir.Approved, Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Ulobetasol.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Ulobetasol.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Ulobetasol.Approved, Investigational
BCG vaccineThe risk or severity of adverse effects can be increased when Ulobetasol is combined with BCG vaccine.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Ulobetasol.Experimental
BendroflumethiazideUlobetasol may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Ulobetasol.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Ulobetasol.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Ulobetasol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Ulobetasol.Experimental
Bismuth SubcitrateThe bioavailability of Ulobetasol can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of Ulobetasol can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe serum concentration of Ulobetasol can be increased when it is combined with Boceprevir.Approved, Withdrawn
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Ulobetasol.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Ulobetasol.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Ulobetasol.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Ulobetasol.Experimental
BumetanideUlobetasol may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Ulobetasol.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Ulobetasol can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of Ulobetasol can be decreased when combined with Calcium silicate.Experimental
Capromab pendetideUlobetasol may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe serum concentration of Ulobetasol can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Ulobetasol.Experimental, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Ulobetasol.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Ulobetasol.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Ulobetasol.Approved, Investigational
CeritinibUlobetasol may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Ulobetasol.Approved, Vet Approved
ChlorothiazideUlobetasol may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Ulobetasol can be increased when it is combined with Chlorotrianisene.Investigational, Withdrawn
ChlorthalidoneUlobetasol may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Ulobetasol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Ulobetasol.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Cinoxacin.Approved, Investigational, Withdrawn
ClarithromycinThe serum concentration of Ulobetasol can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Ulobetasol.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Ulobetasol is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
CobicistatThe serum concentration of Ulobetasol can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Ulobetasol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Ulobetasol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensThe serum concentration of Ulobetasol can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Ulobetasol.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Ulobetasol is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Ulobetasol.Investigational
CyclopenthiazideUlobetasol may increase the hypokalemic activities of Cyclopenthiazide.Experimental
DaidzeinThe serum concentration of Ulobetasol can be increased when it is combined with Daidzein.Experimental
DanazolUlobetasol may increase the fluid retaining activities of Danazol.Approved
DarunavirThe serum concentration of Ulobetasol can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Demecarium.Approved
DersalazineThe risk or severity of adverse effects can be increased when Dersalazine is combined with Ulobetasol.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Ulobetasol.Approved, Vet Approved
DienestrolThe serum concentration of Ulobetasol can be increased when it is combined with Dienestrol.Approved, Investigational
DiethylstilbestrolThe serum concentration of Ulobetasol can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Ulobetasol.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ulobetasol.Approved
DistigmineThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Ulobetasol.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Ulobetasol.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Ulobetasol.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Ulobetasol can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Ulobetasol can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Ulobetasol.Approved
EquolThe serum concentration of Ulobetasol can be increased when it is combined with Equol.Investigational
EstradiolThe serum concentration of Ulobetasol can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Ulobetasol can be increased when it is combined with Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Ulobetasol can be increased when it is combined with Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Ulobetasol can be increased when it is combined with Estradiol valerate.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Ulobetasol can be increased when it is combined with Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Ulobetasol can be increased when it is combined with Estrogens, esterified.Approved
EstroneThe serum concentration of Ulobetasol can be increased when it is combined with Estrone.Approved
Etacrynic acidUlobetasol may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Ulobetasol.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Ulobetasol.Experimental
Ethinyl EstradiolThe serum concentration of Ulobetasol can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Ulobetasol.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Ulobetasol.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Ulobetasol.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Ulobetasol.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Ulobetasol.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Ulobetasol.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Ulobetasol.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Ulobetasol.Approved
FenthionThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Ulobetasol.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Ulobetasol.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Ulobetasol.Experimental
FleroxacinThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Ulobetasol.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Ulobetasol.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Ulobetasol.Experimental
FluoxymesteroneUlobetasol may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Ulobetasol.Approved, Investigational
FosaprepitantThe serum concentration of Ulobetasol can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Ulobetasol can be decreased when it is combined with Fosphenytoin.Approved
FurosemideUlobetasol may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Ulobetasol is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Ulobetasol can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Ulobetasol is combined with GI-5005.Investigational
GLPG-0492Ulobetasol may increase the fluid retaining activities of GLPG-0492.Investigational
GrepafloxacinThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Ulobetasol.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Ulobetasol.Experimental
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Ulobetasol is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HexestrolThe serum concentration of Ulobetasol can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Ulobetasol.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ulobetasol.Approved, Investigational
HydrochlorothiazideUlobetasol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideUlobetasol may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of Ulobetasol can be decreased when combined with Hydrotalcite.Experimental, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Ulobetasol.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Ulobetasol.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Ulobetasol.Approved
IdelalisibThe serum concentration of Ulobetasol can be increased when it is combined with Idelalisib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Ulobetasol.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Ulobetasol.Approved
IndapamideUlobetasol may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Ulobetasol can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Ulobetasol.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Ulobetasol.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Ulobetasol.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Ulobetasol is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Ulobetasol is combined with INGN 225.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Ipidacrine.Experimental
IsoflurophateThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Ulobetasol.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Ulobetasol.Withdrawn
ItraconazoleThe serum concentration of Ulobetasol can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Ulobetasol.Experimental
KetoconazoleThe serum concentration of Ulobetasol can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Ulobetasol.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Ulobetasol.Approved
LacidipineThe serum concentration of Lacidipine can be decreased when it is combined with Ulobetasol.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Ulobetasol.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Ulobetasol.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Ulobetasol.Experimental
LopinavirThe serum concentration of Ulobetasol can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Ulobetasol.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Ulobetasol.Approved, Investigational
LumacaftorThe serum concentration of Ulobetasol can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Ulobetasol.Approved, Investigational
MagaldrateThe bioavailability of Ulobetasol can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe bioavailability of Ulobetasol can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of Ulobetasol can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Ulobetasol can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Ulobetasol.Approved
Magnesium silicateThe bioavailability of Ulobetasol can be decreased when combined with Magnesium silicate.Approved, Experimental
Magnesium TrisilicateThe bioavailability of Ulobetasol can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Ulobetasol.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ulobetasol.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Ulobetasol.Approved
MefloquineThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Ulobetasol.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Ulobetasol.Approved
MesteroloneUlobetasol may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Ulobetasol can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Ulobetasol.Investigational, Withdrawn
MethallenestrilThe serum concentration of Ulobetasol can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideUlobetasol may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Ulobetasol.Approved, Vet Approved
MethyltestosteroneUlobetasol may increase the fluid retaining activities of Methyltestosterone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Metoclopramide.Approved, Investigational
MetolazoneUlobetasol may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Ulobetasol can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Minaprine.Approved
MitotaneThe serum concentration of Ulobetasol can be decreased when it is combined with Mitotane.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Ulobetasol.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Ulobetasol.Experimental
MoxestrolThe serum concentration of Ulobetasol can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ulobetasol.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ulobetasol.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Ulobetasol.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Ulobetasol.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Ulobetasol.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Nalidixic Acid.Approved, Investigational
NandroloneUlobetasol may increase the fluid retaining activities of Nandrolone.Experimental, Investigational
Nandrolone decanoateUlobetasol may increase the fluid retaining activities of Nandrolone decanoate.Approved, Illicit
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Ulobetasol.Approved, Vet Approved
NefazodoneThe serum concentration of Ulobetasol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Ulobetasol can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Ulobetasol.Approved
NevirapineThe serum concentration of Ulobetasol can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Ulobetasol.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Ulobetasol.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Ulobetasol.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Ulobetasol.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Norfloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ulobetasol.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Ulobetasol.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Ulobetasol.Vet Approved
OxandroloneUlobetasol may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Ulobetasol.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Oxolinic acid.Experimental
OxymetholoneUlobetasol may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Ulobetasol.Approved, Withdrawn
ParaoxonThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Ulobetasol.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Ulobetasol.Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Ulobetasol can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of Ulobetasol can be decreased when it is combined with Phenobarbital.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ulobetasol.Approved, Vet Approved
PhenytoinThe serum concentration of Ulobetasol can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ulobetasol.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Pipemidic acid.Experimental
PiretanideUlobetasol may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Ulobetasol.Approved, Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Ulobetasol.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Ulobetasol.Experimental
Polyestradiol phosphateThe serum concentration of Ulobetasol can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideUlobetasol may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Ulobetasol can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Ulobetasol.Experimental, Investigational
PrimidoneThe serum concentration of Ulobetasol can be decreased when it is combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Ulobetasol.Experimental
PromestrieneThe serum concentration of Ulobetasol can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Ulobetasol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Ulobetasol.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Ulobetasol.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Ulobetasol.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Ulobetasol can be increased when it is combined with Quinestrol.Approved
QuinethazoneUlobetasol may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Rabies virus inactivated antigen, A.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Ulobetasol.Approved, Experimental, Investigational
RifabutinThe serum concentration of Ulobetasol can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Ulobetasol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Ulobetasol can be decreased when it is combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Rindopepimut.Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Ulobetasol.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Rosoxacin.Approved, Investigational
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Rubella virus vaccine.Approved
RufloxacinThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Ulobetasol.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Ulobetasol.Approved, Vet Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Salmonella typhi ty21a live antigen.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Ulobetasol.Approved
SaquinavirThe serum concentration of Ulobetasol can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Ulobetasol can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Ulobetasol.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Ulobetasol.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Ulobetasol.Investigational
SitafloxacinThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Sitafloxacin.Experimental, Investigational
Sodium bicarbonateThe bioavailability of Ulobetasol can be decreased when combined with Sodium bicarbonate.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Sparfloxacin.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Ulobetasol is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Ulobetasol.Investigational
St. John's WortThe serum concentration of Ulobetasol can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StanoloneUlobetasol may increase the fluid retaining activities of Stanolone.Illicit, Investigational
StanozololUlobetasol may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Ulobetasol can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ulobetasol.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Ulobetasol.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Ulobetasol.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Ulobetasol.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Ulobetasol can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Ulobetasol can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Tacrine.Investigational, Withdrawn
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Ulobetasol.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Ulobetasol.Approved, Withdrawn
TelithromycinThe serum concentration of Ulobetasol can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Ulobetasol.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Ulobetasol.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Ulobetasol.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Ulobetasol.Approved
TestosteroneUlobetasol may increase the fluid retaining activities of Testosterone.Approved, Investigational
Testosterone CypionateUlobetasol may increase the fluid retaining activities of Testosterone Cypionate.Approved, Investigational
Testosterone EnanthateUlobetasol may increase the fluid retaining activities of Testosterone Enanthate.Approved, Investigational
Testosterone PropionateUlobetasol may increase the fluid retaining activities of Testosterone Propionate.Approved, Vet Approved
Testosterone UndecanoateUlobetasol may increase the fluid retaining activities of Testosterone Undecanoate.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Ulobetasol is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Ulobetasol.Approved
TiboloneThe serum concentration of Ulobetasol can be increased when it is combined with Tibolone.Approved, Investigational
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Ulobetasol.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Ulobetasol.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Ulobetasol.Approved
TorasemideUlobetasol may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Ulobetasol.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Ulobetasol.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Trichlorfon.Vet Approved
TrichlormethiazideUlobetasol may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Ulobetasol.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Ulobetasol.Approved
TromethamineThe bioavailability of Ulobetasol can be decreased when combined with Tromethamine.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Ulobetasol.Investigational, Withdrawn
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Ulobetasol is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
VoriconazoleThe serum concentration of Ulobetasol can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinUlobetasol may increase the anticoagulant activities of Warfarin.Approved
Yellow fever vaccineThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Yellow fever vaccine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Ulobetasol.Approved, Investigational
ZeranolThe serum concentration of Ulobetasol can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Ulobetasol.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Ulobetasol.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Daniella Gutman, Shimon Chernyak, "Process for preparing a crystalline form of halobetasol propionate." U.S. Patent US20070167420, issued July 19, 2007.

US20070167420
General References
Not Available
External Links
PubChem Compound
5311167
PubChem Substance
46506187
ChemSpider
4470691
ChEMBL
CHEMBL1201360
Therapeutic Targets Database
DAP001186
PharmGKB
PA164768832
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Ulobetasol
ATC Codes
D07AC21 — Ulobetasol
AHFS Codes
  • 84:06.00 — Anti-inflammatory Agents
FDA label
Download (399 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers2
1CompletedTreatmentPsoriasis1
2CompletedTreatmentPlaque Psoriasis1
2CompletedTreatmentPsoriasis2
2Not Yet RecruitingTreatmentPlaque Psoriasis1
2, 3CompletedTreatmentPsoriasis1
3CompletedTreatmentPlaque Psoriasis1
3RecruitingTreatmentPlaque Psoriasis2

Pharmacoeconomics

Manufacturers
  • Altana inc
  • G and w laboratories inc
  • Perrigo israel pharmaceuticals ltd
  • Taro pharmaceuticals usa inc
  • Ranbaxy laboratories inc
  • Actavis mid atlantic llc
  • Perrigo co
Packagers
Dosage forms
FormRouteStrength
CreamTopical.5 mg/g
OintmentTopical.5 mg/g
LotionTopical.5 mg/g
CreamTopical0.05 %
OintmentTopical0.05 %
Kit
Prices
Unit descriptionCostUnit
Ultravate 0.05% Ointment 50 gm Tube180.27USD tube
Ultravate 0.05% Cream 50 gm Tube152.54USD tube
Halobetasol Propionate 0.05% Cream 50 gm Tube79.14USD tube
Halobetasol Propionate 0.05% Ointment 50 gm Tube79.14USD tube
Ultravate 0.05% Ointment 15 gm Tube64.78USD tube
Ultravate 0.05% Cream 15 gm Tube63.16USD tube
Halobetasol Propionate 0.05% Cream 15 gm Tube32.92USD tube
Halobetasol Propionate 0.05% Ointment 15 gm Tube32.92USD tube
Ultravate 0.05% cream4.07USD g
Halobetasol prop 0.05% cream1.8USD g
Ultravate 0.05 % Cream0.9USD g
Ultravate pac kit0.59USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8962028No2013-06-192033-06-19Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityMostly insolubleNot Available
logP2.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.022 mg/mLALOGPS
logP2.93ALOGPS
logP2.7ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)12.46ChemAxon
pKa (Strongest Basic)-3.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area74.6 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity105.37 m3·mol-1ChemAxon
Polarizability42.07 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9974
Blood Brain Barrier+0.9789
Caco-2 permeable+0.5865
P-glycoprotein substrateSubstrate0.7448
P-glycoprotein inhibitor IInhibitor0.6948
P-glycoprotein inhibitor IINon-inhibitor0.8943
Renal organic cation transporterNon-inhibitor0.857
CYP450 2C9 substrateNon-substrate0.8553
CYP450 2D6 substrateNon-substrate0.9136
CYP450 3A4 substrateSubstrate0.7689
CYP450 1A2 substrateNon-inhibitor0.9093
CYP450 2C9 inhibitorNon-inhibitor0.885
CYP450 2D6 inhibitorNon-inhibitor0.7394
CYP450 2C19 inhibitorNon-inhibitor0.8972
CYP450 3A4 inhibitorInhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8771
Ames testNon AMES toxic0.8762
CarcinogenicityNon-carcinogens0.8902
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.3204 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9723
hERG inhibition (predictor II)Non-inhibitor0.6521
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Pregnane steroids
Direct Parent
Gluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
20-oxosteroids / 11-beta-hydroxysteroids / 17-hydroxysteroids / 3-oxo delta-1,4-steroids / Halogenated steroids / Delta-1,4-steroids / Tertiary alcohols / Alpha-hydroxy ketones / Alpha-chloroketones / Secondary alcohols
show 9 more
Substituents
Progestogin-skeleton / 20-oxosteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / 9-halo-steroid / 6-halo-steroid / 17-hydroxysteroid / 11-hydroxysteroid / 11-beta-hydroxysteroid / Halo-steroid
show 26 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Mohandas S, Rai R, Srinivas CR: Halobetasol versus clobetasol: a study of potency. Indian J Dermatol Venereol Leprol. 2009 Mar-Apr;75(2):186-7. [PubMed:19293512]
  2. Hofmann TG, Hehner SP, Bacher S, Droge W, Schmitz ML: Various glucocorticoids differ in their ability to induce gene expression, apoptosis and to repress NF-kappaB-dependent transcription. FEBS Lett. 1998 Dec 28;441(3):441-6. [PubMed:9891987]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Steroid binding
Specific Function
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name
SERPINA6
Uniprot ID
P08185
Uniprot Name
Corticosteroid-binding globulin
Molecular Weight
45140.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Drug created on June 13, 2005 07:24 / Updated on January 15, 2018 08:44